Basit öğe kaydını göster

dc.contributor.authorAkbas M,Koyuncu FM,Artunc-Ulkumen B,Taneli F,Ozdemir H
dc.date.accessioned2023-03-02T11:24:32Z
dc.date.available2023-03-02T11:24:32Z
dc.date.issued2020
dc.identifier.urihttp://hdl.handle.net/20.500.12481/16113
dc.description.abstractObjective: Perlecan is an extracellular matrix proteoglycan suggested to maintain endothelial functions. We aimed to measure maternal serum perlecan levels in different preeclampsia phenotypes. Methods: This study included 50 women with preeclampsia and 30 healthy pregnant women. Results: Serum perlecan levels were significantly higher (p = 0.016) in preeclamptic women with severe features(n = 23) than preeclampsia patients(n = 27). There were no statistically significant differences in serum perlecan levels between the early-onset preeclampsia(n = 25), late-onset preeclampsia(n = 25), and healthy pregnancies. Conclusion: Our findings suggest that preeclamptic women with severe features have higher serum perlecan levels than women with preeclampsia. © 2020, © 2020 Informa UK Limited, trading as Taylor & Francis Group.
dc.titleMaternal serum perlecan levels in women with preeclampsia
dc.identifier.DOI-ID10.1080/10641955.2019.1711390
dc.identifier.volume39
dc.identifier.issue1
dc.identifier.startpage70
dc.identifier.endpage76
dc.identifier.issn/e-issn1064-1955


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

  • Scopus [2994]
    Scopus İndeksli Yayınlar Koleksiyonu

Basit öğe kaydını göster